EMA committee recommends Nyxoid naloxone nasal spray for opioid overdose without a prescription
- In October 2026 the EMA's human medicines committee recommended making Nyxoid (naloxone) available without a prescription.
- Nyxoid is a nasal spray for emergency treatment of known or suspected opioid overdose, such as heroin or morphine.
- Naloxone nasal spray Nyxoid has been authorised in the EU since 2017 but required a prescription.
- The recommendation on Nyxoid came at the committee's 12–15 October 2026 meeting.
At its meeting of 12–15 October 2026, the European Medicines Agency's human medicines committee (CHMP) recommended changing the legal status of Nyxoid (naloxone) so that it can be supplied without a medical prescription.
What Nyxoid is
Nyxoid is a nasal spray containing naloxone, used for emergency treatment of known or suspected overdose of opioid drugs such as heroin or morphine. Naloxone reverses the effects of opioids, including the slowed breathing that makes an overdose life-threatening.
Also read: EMA recommends Foundayo (orforglipron), a once-daily GLP-1 tablet for obesity and type 2 diabetes
Why it matters
The spray received EU-wide authorisation in 2017 for adults and adolescents aged 14 and over, but it has been prescription-only. Over-the-counter access could make it easier for families and people around opioid users to obtain and carry it, so it can be used quickly before emergency services arrive.
Next step
Like other CHMP opinions, the recommendation needs a European Commission decision before it takes effect. Naloxone is first aid, not a substitute for emergency care: its effect can wear off before the opioid's does.
Sources: EMA — CHMP meeting highlights, October 2026, EMA — Nyxoid EPAR
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is Nyxoid?
Nyxoid is a naloxone nasal spray used for emergency treatment of known or suspected overdose of opioids such as heroin or morphine.
What did the EMA recommend for Nyxoid?
In October 2026 the EMA's CHMP recommended changing Nyxoid's legal status so that it is available without a medical prescription.
How does naloxone work?
Naloxone reverses the effects of opioids in the body, including the depressed breathing that makes an opioid overdose life-threatening.
Who is Nyxoid authorised for in the EU?
Nyxoid has been authorised in the EU since 2017 for adults and adolescents aged 14 years and over.
Does a naloxone spray replace calling an ambulance?
No. A naloxone spray is first aid only; emergency help must always be called because its effect can wear off before the opioid's effect does.



